₹1,061.50
1.51%
Compare
Alivus Life Sciences vs Sun PharmaceuticalAlivus Life Sciences vs Divi's LaboratoriesAlivus Life Sciences vs Piramal PharmaAlivus Life Sciences vs Eris LifesciencesAlivus Life Sciences vs Neuland LaboratoriesAlivus Life Sciences vs NIFTY 50 | MarketN

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Dec 2024

Income Metrics

Revenue 6.4B
Gross Profit 3.6B 55.55%
Operating Income 1.8B 27.29%
Net Income 1.4B 21.34%
EPS (Diluted) ₹11.14

Balance Sheet Metrics

Total Assets 30.8B
Total Liabilities 5.5B
Shareholders Equity 25.4B
Debt to Equity 0.22

Cash Flow Metrics

Revenue & Profitability Trend

Quarter Income Flow i

Annual Income Flow i

Alivus Life Sciences Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 21.8B 20.5B 20.9B 18.6B 14.9B
Cost of Goods Sold i 10.2B 10.3B 10.6B 9.2B 7.0B
Gross Profit i 11.6B 10.2B 10.3B 9.5B 7.9B
Gross Margin % i 53.3% 49.6% 49.3% 50.8% 53.0%
Operating Expenses
Research & Development i - - 0 2.9M 0
Selling, General & Administrative i 395.6M 337.7M 309.8M 412.8M 334.9M
Other Operating Expenses i 2.2B 2.2B 1.9B 1.4B 1.4B
Total Operating Expenses i 2.5B 2.5B 2.2B 1.8B 1.8B
Operating Income i 6.2B 6.0B 5.8B 5.6B 4.4B
Operating Margin % i 28.5% 29.3% 27.7% 30.2% 29.7%
Non-Operating Items
Interest Income i 120.2M 157.7M 67.8M 4.3M 3.6M
Interest Expense i 15.5M 5.5M 279.6M 875.5M 335.2M
Other Non-Operating Income - - - - -
Pre-tax Income i 6.3B 6.3B 5.6B 4.7B 4.2B
Income Tax i 1.6B 1.6B 1.5B 1.2B 1.1B
Effective Tax Rate % i 25.4% 25.7% 25.9% 25.3% 25.6%
Net Income i 4.7B 4.7B 4.2B 3.5B 3.1B
Net Margin % i 21.6% 22.8% 20.1% 18.9% 21.0%
Key Metrics
EBITDA i 6.9B 6.7B 6.3B 5.9B 4.9B
EPS (Basic) i ₹38.43 ₹38.11 ₹35.63 ₹28.69 ₹25.55
EPS (Diluted) i ₹38.38 ₹38.11 ₹35.63 ₹28.69 ₹25.55
Basic Shares Outstanding i 122527172 122527172 117525650 122527172 122527172
Diluted Shares Outstanding i 122527172 122527172 117525650 122527172 122527172

Income Statement Trend

Join Our India Telegram Channel

Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!

Join Now →

Alivus Life Sciences Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 3.0B 2.8B 5.1B 1.2B 100.0M
Short-term Investments i 905.5M 440.1M 51.5M 241.6M 207.7M
Accounts Receivable i 7.7B 8.1B 6.7B 6.2B 6.4B
Inventory i 6.7B 6.0B 5.2B 5.1B 4.1B
Other Current Assets 5.2M 6.4M 567.8M - -
Total Current Assets i 19.2B 18.5B 17.6B 14.0B 11.6B
Non-Current Assets
Property, Plant & Equipment i 8.0B 7.7B 5.8B 0 0
Goodwill i 148.5M 180.0M 103.8M 79.1M 71.7M
Intangible Assets i 148.5M 180.0M 103.8M 79.1M 71.7M
Long-term Investments - - - - -
Other Non-Current Assets 10.0K 12.7M 140.7M - -
Total Non-Current Assets i 9.3B 8.5B 7.1B 6.0B 5.7B
Total Assets i 28.5B 27.0B 24.7B 20.0B 17.3B
Liabilities
Current Liabilities
Accounts Payable i 3.7B 4.3B 3.2B 2.2B 2.0B
Short-term Debt i 23.9M 22.6M 16.8M 0 210.0K
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 154.2M 296.8M 34.0M - -
Total Current Liabilities i 4.4B 5.0B 3.8B 12.2B 13.1B
Non-Current Liabilities
Long-term Debt i 147.6M 170.9M 12.0M 0 -
Deferred Tax Liabilities i 487.8M 424.3M 315.0M 228.9M 164.5M
Other Non-Current Liabilities - - - - -
Total Non-Current Liabilities i 793.2M 674.0M 327.0M 228.9M 164.5M
Total Liabilities i 5.2B 5.6B 4.2B 12.4B 13.2B
Equity
Common Stock i 245.0M 245.0M 245.0M 19.6M 19.6M
Retained Earnings i 12.9B 11.0B 10.2B 7.5B -
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 23.3B 21.4B 20.5B 7.5B 4.0B
Key Metrics
Total Debt i 171.5M 193.6M 28.8M 0 210.0K
Working Capital i 14.8B 13.5B 13.8B 1.8B -1.5B

Balance Sheet Composition

Alivus Life Sciences Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i 6.3B 6.3B 5.6B 4.7B 4.2B
Depreciation & Amortization i - - - - -
Stock-Based Compensation i 43.8M 31.8M 35.0M 0 -
Working Capital Changes i -1.6B -3.8B 1.1B -1.9B -2.1B
Operating Cash Flow i 4.7B 2.4B 7.0B 3.7B 2.4B
Investing Activities
Capital Expenditures i -1.3B -1.6B -1.3B -663.6M -508.7M
Acquisitions i - - - - -
Investment Purchases i - - - -28.0M 0
Investment Sales i 0 1.1M 28.0M - -
Investing Cash Flow i -1.3B -1.6B -1.3B -719.7M -508.7M
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i -2.8B -3.9B -1.3B - -
Debt Issuance i - - - - -
Debt Repayment i - - - - -
Financing Cash Flow i -2.8B -3.9B -496.7M -4.3B -1.4B
Free Cash Flow i 2.8B 1.4B 4.7B 3.2B 1.4B
Net Change in Cash i 658.3M -3.1B 5.3B -1.3B 572.4M

Cash Flow Trend

Alivus Life Sciences Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 31.45
Forward P/E 22.31
Price to Book 4.87
Price to Sales 5.66
PEG Ratio 2.05

Profitability Ratios

Profit Margin 53.28%
Operating Margin 28.97%
Return on Equity 20.19%
Return on Assets 16.52%

Financial Health

Current Ratio 4.52
Debt to Equity 0.01

Per Share Data

EPS (TTM) ₹38.38
Book Value per Share ₹207.22
Revenue per Share ₹178.31

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
GLS 123.8B 31.45 4.87 20.19% 53.28% 0.01
Sun Pharmaceutical 3.9T 36.73 5.15 15.08% 19.21% 6.68
Divi's Laboratories 1.7T 67.11 10.82 14.64% 24.04% 0.58
Piramal Pharma 199.7B 269.79 2.47 1.12% -1.84% 60.08
Eris Lifesciences 193.4B 44.25 6.15 10.75% 14.06% 68.19
Neuland Laboratories 184.8B 103.42 11.41 17.06% 2.29% 16.33
Nippun Rana

Nippun Rana

Chasing the market trend!

Hi, I’m Nippun, a tech enthusiast from Haryana, India. I have been coding since 2010 and using my coding skills in the share market since 2020. I have been coding scripts in Pinescript that work on Tradingview app/web. I love learning about new technology and applying it to solve real-world problems. Coding and share-market are my passions, and I enjoy finding and fixing bugs in code. I aim to share my skill set and experience that can positively impact society. Feel free to connect with me, an...

Financial data is updated regularly. All figures are in the company's reporting currency.